Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 367
- Registration Number
- NCT03345914
- Locations
- 🇬🇧
Regeneron Research Site, Sheffield, United Kingdom
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
- Conditions
- Interventions
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1650
- Registration Number
- NCT03304379
- Locations
- 🇺🇸
Advance Research Center, Anaheim, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸Clinical Research Advantage, Inc./Warner Family Practice, PC, Chandler, Arizona, United States
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT03285646
- Locations
- 🇺🇸
Regeneron Research Site #1, Memphis, Tennessee, United States
🇺🇸Regeneron Research Site, Kenosha, Wisconsin, United States
🇺🇸Regeneron Research Site #2, Memphis, Tennessee, United States
Study of Cemiplimab in Adults With Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 608
- Registration Number
- NCT03257267
- Locations
- 🇺🇸
First Health of the Carolinas Outpatient Cancer Center, Pinehurst, North Carolina, United States
🇧🇷Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
🇧🇷Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 145
- Registration Number
- NCT03233139
- Locations
- 🇯🇵
Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Osaka Medical College Hospital, Takatsuki, Osaka, Japan
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT03198130
- Locations
- 🇰🇷
Seoul National University, Seoul, Korea, Republic of
🇰🇷Yonsei University College of Medicine, Severence Hospital, Seoul, Korea, Republic of
🇬🇧University Birmingham, Birmingham, United Kingdom
A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT03188666
- Locations
- 🇮🇹
Giannina Gaslini Institute, Genova, Italy
🇫🇷Hopital Lariboisiere,Hospitalier Universitaire Nord, Paris, France
🇫🇷Hopital Cochin, Paris, France
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 272
- Registration Number
- NCT03175367
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Federico II di Napoli, Napoli, Italy
🇮🇹Dipartimento di Medicina Traslazionale e di Precisione dell'Università degli Studi di, Rome, Italy
🇺🇸Office of Dr. John D Homan MD, Newport Beach, California, United States
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 3307
- Registration Number
- NCT03161093
- Locations
- 🇺🇸
Pacific Arthritis Care Center, Los Angeles, California, United States
🇺🇸Lynn Institute of the Rockies, Colorado Springs, Colorado, United States
🇺🇸Panorama Orthopedics & Spine Center, Golden, Colorado, United States
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT03156621
- Locations
- 🇨🇳
Regeneron Study Site, Taipei, Taiwan
🇺🇦Regeneron Research Site, Kyiv, Ukraine